{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:15:40Z","timestamp":1779887740762,"version":"3.53.1"},"reference-count":37,"publisher":"Society of Nuclear Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.2967\/jnumed.122.265167","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T20:45:13Z","timestamp":1680813913000},"page":"924-931","source":"Crossref","is-referenced-by-count":12,"title":["Cure of Disseminated Human Lymphoma with [<sup>225<\/sup>Ac]Ac-Ofatumumab in a Preclinical Model"],"prefix":"10.2967","volume":"64","author":[{"given":"Mark S.","family":"Longtine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyuhwan","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Hoegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Benabdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane S.","family":"Abou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.J.","family":"Thorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Wahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"2023060112150626000_64.6.924.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"2023060112150626000_64.6.924.2","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2009.11.002"},{"key":"2023060112150626000_64.6.924.3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01245"},{"key":"2023060112150626000_64.6.924.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08966.x"},{"key":"2023060112150626000_64.6.924.5","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-1182"},{"key":"2023060112150626000_64.6.924.6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/ph12040141","article-title":"Radioimmunotherapy in non-Hodgkin\u2019s lymphoma: retrospective adverse event profiling of Zevalin and Bexxar","volume":"12","author":"Sachpekidis","year":"2019","journal-title":"Pharmaceuticals (Basel)."},{"key":"2023060112150626000_64.6.924.7","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2017.74.5083","article-title":"Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus 131I-tositumomab: long-term follow-up of phase III randomized study SWOG-S0016","volume":"36","author":"Shadman","year":"2018","journal-title":"J Clin Oncol."},{"key":"2023060112150626000_64.6.924.8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.critrevonc.2016.07.008","article-title":"Zevalin\u00ae (ibritumomab tiuxetan): after more than a decade of treatment experience, what have we learned?","volume":"105","author":"Rizzieri","year":"2016","journal-title":"Crit Rev Oncol Hematol."},{"key":"2023060112150626000_64.6.924.9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40658-017-0193-4","article-title":"Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey","volume":"4","author":"Sj\u00f6green Gleisner","year":"2017","journal-title":"EJNMMI Phys."},{"key":"2023060112150626000_64.6.924.10","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2174\/1874471011666180502104524","article-title":"An overview of targeted alpha therapy with 225actinium and 213bismuth","volume":"11","author":"Morgenstern","year":"2018","journal-title":"Curr Radiopharm."},{"key":"2023060112150626000_64.6.924.11","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2967\/jnumed.117.203299","article-title":"Evaluation of next-generation anti-CD20 antibodies labeled with 89Zr in human lymphoma xenografts","volume":"59","author":"Yoon","year":"2018","journal-title":"J Nucl Med."},{"key":"2023060112150626000_64.6.924.12","doi-asserted-by":"crossref","unstructured":"Shim K Longtine MS Abou DS . Cure of disseminated human lymphoma with [177Lu]Lu-ofatumumab in a preclinical model. J Nucl Med. November 10, 2022 [Epub ahead of print].","DOI":"10.2967\/jnumed.122.265167"},{"key":"2023060112150626000_64.6.924.13","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s11307-021-01594-0","article-title":"Bioluminescent tumor signal is mouse strain and pelt color dependent: experience in a disseminated lymphoma model","volume":"23","author":"Hoegger","year":"2021","journal-title":"Mol Imaging Biol."},{"key":"2023060112150626000_64.6.924.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.056036"},{"key":"2023060112150626000_64.6.924.15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.058651"},{"key":"2023060112150626000_64.6.924.16","first-page":"7","article-title":"ICRP publication 107: nuclear decay data for dosimetric calculations","volume":"38","author":"Eckerman","year":"2008","journal-title":"Ann ICRP."},{"key":"2023060112150626000_64.6.924.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.138347"},{"key":"2023060112150626000_64.6.924.18","doi-asserted-by":"crossref","first-page":"e0230526","DOI":"10.1371\/journal.pone.0230526","article-title":"Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin\u2019s lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003","volume":"15","author":"Maaland","year":"2020","journal-title":"PLoS One."},{"key":"2023060112150626000_64.6.924.19","doi-asserted-by":"publisher","DOI":"10.1021\/jm990141f"},{"key":"2023060112150626000_64.6.924.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-8051(99)00024-4"},{"key":"2023060112150626000_64.6.924.21","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/56\/3\/012"},{"key":"2023060112150626000_64.6.924.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.07.044"},{"key":"2023060112150626000_64.6.924.23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.263962"},{"key":"2023060112150626000_64.6.924.24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.nucmedbio.2020.07.006","article-title":"Evaluation of [225Ac]Ac-DOTA-anti-VLA-4 for targeted alpha therapy of metastatic melanoma","volume":"88-89","author":"Cortez","year":"2020","journal-title":"Nucl Med Biol."},{"key":"2023060112150626000_64.6.924.25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.251983"},{"key":"2023060112150626000_64.6.924.26","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/cas.15235","article-title":"FZD10-targeted \u03b1-radioimmunotherapy with 225Ac-labeled OTSA101 achieves complete remission in a synovial sarcoma model","volume":"113","author":"Sudo","year":"2022","journal-title":"Cancer Sci."},{"key":"2023060112150626000_64.6.924.27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-175125"},{"key":"2023060112150626000_64.6.924.28","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.107.049502"},{"key":"2023060112150626000_64.6.924.29","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004110945"},{"key":"2023060112150626000_64.6.924.30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-3096"},{"key":"2023060112150626000_64.6.924.31","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1021\/acs.molpharmaceut.7b00985","article-title":"Evaluation of an anti-HER2 nanobody labeled with 225Ac for targeted \u03b1-particle therapy of cancer","volume":"15","author":"Pruszynski","year":"2018","journal-title":"Mol Pharm."},{"key":"2023060112150626000_64.6.924.32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282327"},{"key":"2023060112150626000_64.6.924.33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-612770"},{"key":"2023060112150626000_64.6.924.34","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/s41416-021-01585-6","article-title":"Preclinical study of 212Pb alpha-radioimmunotherapy targeting CD20 in non-Hodgkin lymphoma","volume":"125","author":"Durand-Panteix","year":"2021","journal-title":"Br J Cancer."},{"key":"2023060112150626000_64.6.924.35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-066803"},{"key":"2023060112150626000_64.6.924.36","doi-asserted-by":"crossref","unstructured":"Abou DS Ulmert D Doucet M Hobbs RF Riddle RC Thorek DL . Whole-body and microenvironmental localization of radium-223 in na\u00efve and mouse models of prostate cancer metastasis. J Natl Cancer Inst. 2015;108:djv380.","DOI":"10.1093\/jnci\/djv380"},{"key":"2023060112150626000_64.6.924.37","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-003-1413-9"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.122.265167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T19:19:03Z","timestamp":1685647143000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.122.265167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,1]]},"published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.2967\/jnumed.122.265167"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.122.265167","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,6]]}}}